Nuttall Women’s Health invested in Pheast’s Series A to advance macrophage checkpoint biology as a new therapeutic axis for female-specific cancers. NWH is particularly focused on its potential impact in endometrial and ovarian cancer, where existing immunotherapies have shown limited success.
Share
